Dr. Hedy P. Smith, M.D.
Hematology (Hematology (Internal Medicine) Physician)
- Medicare participating
At a glance
- Medical school
- University of Tennessee, Hsc, College of Medicine (1997)
- Years since graduation
- 29
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 288
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1997Medical school: University of Tennessee, Hsc, College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology (Internal Medicine) Physician primary
MA license 203148 -
Internal Medicine Physician
MA license 203148 -
Medical Oncology Physician
MA license 203148
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Medstar Washington Hospital Center Washington, DC
Medical groups
- Medstar Medical Group II LLC (3,767 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 288
- Services billed
- 691
- Patients’ average age
- 69
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 219 | 115 |
| Established patient office or other outpatient visit, 30-39 minutes | 123 | 94 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 122 | 33 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 80 | 77 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 43 | 16 |
| New patient office or other outpatient visit, 60-74 minutes | 39 | 39 |
| New patient office or other outpatient visit, 45-59 minutes | 26 | 26 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Boston, MA | 52 |
| Hydroxyurea Other prescribers in Boston, MA | 49 |
| Oxycodone Hcl Other prescribers in Boston, MA | 42 |
| Revlimid (lenalidomide) | 33 |
| Ninlaro (ixazomib citrate) | 22 |
| Venclexta (venetoclax) | 21 |
| Eliquis (apixaban) Other prescribers in Boston, MA | 17 |
| Methadone Hcl Other prescribers in Boston, MA | 13 |
| Hydromorphone Hcl Other prescribers in Boston, MA | 12 |
| Ondansetron Hcl Other prescribers in Boston, MA | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 16 companies reported 27 payments worth $2,567 in total to this clinician.
| Agios Pharmaceuticals, Inc. | $1,777 |
|---|---|
| Chiesi USA, Inc. | $300 |
| Celgene Corporation | $97.00 |
| Novartis Pharmaceuticals Corporation | $53.69 |
| Merck Sharp & Dohme LLC | $52.35 |
| Pfizer Inc. | $43.73 |
| Incyte Corporation | $42.03 |
| Caris Mpi, Inc. | $34.97 |
| Travel and Lodging | $1,400 |
|---|---|
| Food and Beverage | $866 |
| Honoraria | $300 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Agios Pharmaceuticals, Inc. Oct 19, 2025 | Travel and Lodging PYRUKYND · Genetically Defined Disease · travel to Boston, MA | $894 |
| Agios Pharmaceuticals, Inc. Oct 19, 2025 | Travel and Lodging PYRUKYND · Genetically Defined Disease · travel to Boston, MA | $349 |
| Chiesi USA, Inc. Mar 14, 2025 | Honoraria FERRIPROX · TREAT IRON OVERLOAD FROM THALASSEMIA, SICKLE CELL OR ANOTHER ANEMIA | $300 |
| Agios Pharmaceuticals, Inc. Oct 19, 2025 | Travel and Lodging PYRUKYND · Genetically Defined Disease · travel to Boston, MA | $157 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 3 companies. The companies reported $122,200 in research payments for these studies, mostly to the institutions running them.
- A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease
Agios Pharmaceuticals, Inc. - A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter, Dose- Finding, Efficacy, and Safety Study of Tebapivat in Participants With Sickle Cell Disease
Agios Pharmaceuticals, Inc. - A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma
AbbVie Inc. · Active, not recruiting · NCT05451810 - M23-362 - A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
AbbVie Inc. - Research Study CSEG101AUS012T
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.